Wordt geladen...
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study
Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is <18 months. This study was designed to determine if maintenance lenalidomid...
Bewaard in:
| Gepubliceerd in: | Br J Haematol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5923897/ https://ncbi.nlm.nih.gov/pubmed/26913697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13957 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|